SCHEMBL8364743

SCHEMBL8364743

CC(C)(C)OC(=O)NC(COS(C)(=O)=O)C(c1ccccc1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSK P43235 4/20 0.47
CTSS P25774 3/20 0.47
TACR1 P25103 1/20 0.43
MAPT P10636 2/20 0.42
CA1 P00915 2/20 0.42
CA7 P43166 2/20 0.42
CA12 O43570 1/20 0.42
CA14 Q9ULX7 1/20 0.42
PPARA Q07869 2/20 0.42
ATM Q13315 2/20 0.42
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA9 Q16790 1/20 0.41
MMP13 P45452 2/20 0.41
KLK5 Q9Y337 1/20 0.41
PPARG P37231 1/20 0.41
CTSL P07711 1/20 0.40
CTSB P07858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18796304 1.00 CTSK (0.47) CTSKCTSSTACR1MAPTCA1
SCHEMBL18796337 0.88 CTSS (0.42) CTSKCTSSCA1CA7PPARA
SCHEMBL4160654 0.85 CTSK (0.49) CTSKCTSSMAPTCA1CA7
SCHEMBL669318 0.85 CTSK (0.49) CTSKCTSSMAPTCA1CA7
SCHEMBL669317 0.85 CTSK (0.49) CTSKCTSSMAPTCA1CA7
SCHEMBL2126884 0.81 CTSK (0.53) CTSKCTSSMAPTCA1CA7
SCHEMBL2126887 0.81 CTSK (0.53) CTSKCTSSMAPTCA1CA7
SCHEMBL16181500 0.81 CTSK (0.53) CTSKCTSSMAPTCA1CA7
SCHEMBL2601218 0.81 CTSK (0.53) CTSKCTSSMAPTCA1CA7
SCHEMBL10188460 0.80 CTSK (0.52) CTSKCTSSMAPTCA1CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9988390-B2 Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2018-06-05 US disclosed
US-20170267680-A1 Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-09-21 US disclosed
WO-2017072341-A1 PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2017-05-04 WO disclosed
US-5929067-A N-ACYLATING AMINE DERIVATIVE OF CAPROLACTAM COMPOUND WITH A CARBOXYLIC ACID OR DERIVATIVES TO FORM AMIDE DERIVATIVE OF CAPROLACTAM COMPOUND NOVARTIS AG (CH) 1999-07-27 US disclosed
EP-0810991-B1 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS NOVARTIS AG (CH) 1999-04-14 EP disclosed
EP-0810991-A1 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS Novartis AG (CH) 1997-12-10 EP disclosed
WO-1996026183-A1 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS NOVARTIS AG (CH) 1996-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267680-A1 Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease XDH, HPRT1, IMPDH1 CTSK 4562/4885CTSS 3988/4885TACR1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.